

April 15, 2019

The preclinical and clinical progress of AMD treatment with RBM-007 is presented at ARVO 2019 Annual Meeting in Vancouver

We are pleased to announce that the preclinical and clinical progress of AMD treatment with RBM-007 will be presented at the annual meeting of ARVO (The Association for Research in Vision and Ophthalmology). ARVO is the largest and most respected eye and vision research organization in the world and the selection of podium presentation is highly competitive and prestigious. ARVO 2019 is going to be held during April 27 and May 2, 2019, in Vancouver. The paper will be presented by Robert B. Bhisitkul, M.D., Ph.D., Professor at University of California San Francisco, and an executive scientific advisor of RIBOMIC Inc.

The presentation includes preclinical and clinical studies of RBM-007 (anti-FGF2 aptamer) targeting neovascular age-related macular degeneration AMD (nAMD). In preclinical studies, we have found that RBM-007 was able to inhibit FGF2-induced angiogenesis, laser-induced choroidal neovascularization and the resulting subretinal fibrosis in animal models of retina disease (i.e., anti-angiogenic and anti-scarring dual action). RBM-007 is now in Phase I/IIa clinical trial (named as SUSHI study) for nAMD in the United States. Part of the Phase I/IIa clinical data will be discussed at the meeting.

For the retina disease community and patients, it is a big disappointment that over the past decade there have been no new-in-class medications since the advent of anti-VEGFs in 2006. We believe that a new mode of action of RBM-007 holds promise as a novel therapy for nAMD as an additive or alternative agent to anti-VEGF treatments.